PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Diethylcarbamazine→

Diethylcarbamazine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
90-89-1
PubChem CID
3052
Molecular formula
C10H21N3O
Molecular weight
199.29 g/mol
Drug class
Antifilarial anthelminticpiperazine derivative
Mechanism of action
Alters microfilarial surface membrane and neuromuscular function, enhancing host immune clearance of filarial parasites. It also has activity against adult worms depending on species and regimen.
Indications / reported uses
  • Treatment of lymphatic filariasis caused by susceptible Wuchereria bancrofti or Brugia species
  • Treatment of loiasis caused by Loa loa and selected other filarial infections under specialist guidance; dosing requires species identification and assessment of microfilarial burden

Sources: CDC — Clinical treatment of lymphatic filariasis · WHO — Lymphatic filariasis treatment guidance · FDA product information

Identification source: PubChem record (CID 3052). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Diethylcarbamazine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Diethylcarbamazine Permitted Daily Exposure (PDE) report (the Diethylcarbamazine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Diethylcarbamazine Occupational Exposure Limit (OEL) report (the Diethylcarbamazine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.